Explore the vast range of titles available.

Vitrimers are covalently crosslinked polymers that behave as conventional thermosets below the glass transition temperature (Tg) but can flow above a particular temperature, Tv > Tg, by bond exchange reactions. In epoxy vitrimers, transesterification reactions are responsible for their behavior at T > Tv that enables flow, thermoforming, recycling, self-healing and stress relaxation. A statistical analysis based on the fragment approach was performed to analyze the evolution of the network structure of epoxy vitrimers during transesterification reactions. An analytical solution was obtained for a formulation based on a diepoxide and a dicarboxylic acid. A numerical solution was derived for the reaction of a diepoxide with a tricarboxylic acid, as an example of the way to apply the model to polyfunctional monomers. As transesterification acts as a disproportionation reaction that converts two linear fragments (monoesters) into a terminal fragment (glycol) and a branching fragment (diester), its effect on network structure is to increase the concentration of crosslinks and pendant chains while leaving a sol fraction. Changes in the network structure of the epoxy vitrimer can take place after their synthesis, during their use at high temperatures, a fact that has to be considered in their technological applications.

\"In this... book, civil rights historian and political analyst Juan Williams denounces Donald Trump for intentionally twisting history to fuel racial tensions for his political advantage. In Williams's lifetime, crusaders for civil rights have braved hatred, violence, and imprisonment, and in so doing made life immeasurably better for African Americans and other marginalized groups. Remarkably, all this progress suddenly seems to have been forgotten--or worse, undone. The stirring history of hard-fought and heroic battles for voting rights, integrated schools, and more is under direct threat from an administration dedicated to restricting these basic freedoms. Williams pulls the fire alarm on the Trump administration's policies, which pose a threat to civil rights without precedent in modern America. What the Hell Do You Have to Lose? makes a searing case for the enduring value of our historic accomplishments and what happens if they are lost.\"-- Provided by publisher.

Economic inequality continues to be one of America's most hotly debated topics.Still, there has been relatively little discussion of the fact that black-white gaps in joblessness, income, poverty and other measures were shrinking before the pandemic. Why was it happening, and why did this phenomenon go unacknowledged by so much media?.

Hydrocephalus due to neurocysticercosis usually shows poor prognosis and shunt failure is a common complication. Neuroendoscopy has been suggested as treatment, but the indications remain unclear. A cohort of patients with clinical/radiological diagnosis of hydrocephalus due to NCC, treated between January 2002 and September 2006, were the subjects of the study. We excluded patients with tumors or those in whom diagnosis was not confirmed (histology/positive ELISA in CSF). Neuroendoscopy was offered as the first line of treatment. Shunt failure rate and Karnofsky index at 12 months were assessed. Eighty-six patients (47 male) with a median age of 38 (9–79) were included in the study. Of them, 36.1% had a shunt before endoscopy and 97.7% had a Karnofsky index <80. We did not find the parasite in 18.6%, extraction was achieved in 79%, and in 87.2% an endoscopic third ventriculostomy (ETV) was performed. The median follow-up time was 43 months (1–72). Shunt failure was seen in 6.6% of patients with ETV in comparison to 27.2% in those without ETV. A hazard ratio of 0.22 (95% CI, 0.05–0.93) for shunt failure after ETV was calculated. At 12 months, 20.9% had a Karnofsky index <80. Early extraction of parasite plus ETV might allow improving outcome and reducing shunt failure. Limitation of inflammatory stimulation by parasite antigens and improvement of CSF dynamics could be an explanation for these findings.

Amnesia is a common sequela following traumatic brain injury (TBI), for which there is no current treatment. Pleiotropic effects of statins have demonstrated faster recovery of spatial memory after TBI in animals. We conducted a double-blind randomized clinical trial add-on of patients with TBI (16–50 years of age), with Glasgow Coma Scale (GCS) scores of 9—13, and intracranial lesions as demonstrated by computed tomography (CT) scan. We excluded those patients with recent head injury or severe disability; administration of known drugs as modifiers of statin metabolism; multisystemic trauma; prior use of mannitol, barbiturate, corticosteroids, indomethacin or calcium antagonists; surgical or isolated lesion in brainstem; allergy to statins; previous hepatopathy or myopathy; previous management in another clinic; or pregnancy. Each patient received the same treatment and was randomly allocated to receive either rosuvastatin (RVS) or placebo over a period of 10 days. The primary outcome measures assessed were amnesia and disorientation times using Galveston Orientation Amnesia Test. Additionally, we evaluated plasma levels of interleukin (IL) 1β, tumor necrosis factor (TNF) α, and IL-6, as well as disability at 3 months. We analyzed eight patients with RVS and 13 controls with similar basal characteristics. Using Cox regression analysis, administration of RVS showed a reduction of amnesia time with a hazard ratio of 53.76 (95% confidence interval [CI], 1.58–1824.64). This was adjusted for early intubation, basal leukocytes, basal Marshall and Fisher score, change of IL-1β levels, and lesion side. IL-6 values at day 3 were increased in the RVS group (p = 0.04). No difference was detected in disability at 3 months. While statins may reduce amnesia time after TBI, possibly by immunomodulation, further trials are needed in order to confirm this positive association.

Background Prolactinomas are the most frequent functional pituitary tumors, accounting for at least 45% of all adenomas. These tumors are more frequently diagnosed in women during their reproductive life of 20-40 years of age, probably due to an early effect of the elevation of PRL causing menstrual irregularities. Hyperprolactinemia is responsible for one third of all cases of female infertility. Macroprolactinomas are less frequent. It presents in males much less frequently. Galactorrhea is seen more in females, very rarely in males. Clinical Case 53-year-old male with severe occipital cephalic pain and hyperprolactinemia, referred to us by the Department of Neurology for endocrinological research due to the finding of a 1.5 cm×1.1 cm Pituitary Macroadenoma (producer of PRL hormone). Treated with Cabergoline 0.5 mg weekly several months ago. Clinical Exam: Male with a height of 70\". Weight 210 lbs. Very marked Gynecomastia to the extent that under digital pressure there is important milk secretion (Photo 1). Neck 42 cm. Thorax 42\". Abdomen 40\". TA120 / 80. RR16 p.m. HR72 p.m. BLOOD HORMONE TEST: IGF-1 230 ng / mL (NV: 64.0-218 ng / mL). Free Testosterone 9.38 pg / mL (NV: 4.25-30.37 pg / mL). ACTH a.m. 30.7 pg / mL (NV: 7.2-63.3 pg / mL). Cortisol a.m. 8.23 ​​ug /dL (NV: 6.0-18.4 ug / dL). Total Estrogens 235 pg / mL (NV: 40-115 pg / mL). FSH 5.4 mIU / mL (NV: 1.5-12.4 mIU / mL). Baseline HGH: 0.2 ng/mL (NV: 0.0-1.2 ng / mL). LH 6.9 mIU/mL (NV: 1.7-8.6 mIU/mL). PRL 0.40 ng/mL (NV: 4.04-15.20 ng/mL) (taking Cabergoline 0.5 mg weekly). Total Testosterone 8.27 ng/mL (NV: 1.93-7.40 ng/mL). TSH 1.64 μIU/mL (0.27-4.20 μIU/mL). FT4 1.33 ng/dL (NV: 0.93-1.71 ng/dL). IMAGES: Campimetry: alterations in both eyeballs (Photo 2-3). Cephalic MRI: Pituitary mass 1.5 cm.×1.1 cm. that contacts the right internal carotid artery as a Macroadenoma (Photo: 3-4-5). Conclusions 1.-Pituitary macroprolactinoma of 1.5 cm.×1.1 cm that contacts the right internal carotid artery accompanied by bilateral breast milk discharge in a male (extremely rare) whose PRL hormone is greatly decreased after prolonged therapy with Cabergoline 0.5 mg weekly. 2.-It will be evaluated by Neurosurgery to weight the possible transsphenoidal / transcranial surgery given the contact of the tumor with the right internal carotid artery. References Prolactinoma | The Pituitary Foundation. (n.d.). Pituitary.org.uk. Retrieved January 4, 2022, from https://pituitary.org.uk/information/pituitary-conditions/prolactinoma/ Prolactinoma - Diagnosis and treatment - Mayo Clinic. (2018). Mayoclinic.org. https://www.mayoclinic.org/diseases-conditions/prolactinoma/diagnosis-treatment/drc-20376962 Ma, Q., Su, J., Li, Y., Wang, J., Long, W., Luo, M., & Liu, Q. (2018). The Chance of Permanent Cure for Micro- and Macroprolactinomas, Medication or Surgery? A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 9. https://doi.org/10.3389/fendo.2018.00636 Presentation: Monday, June 13, 2022 12:30 p.m. - 2:30 p.m.